I-MAB (IMAB) Earnings Date & Reports

Get AI intraday signals

A.I. Advisor

published Earnings

IMAB is expected to report earnings to rise 16.27% to -12 cents per share on November 29

Q3'23

Est.

$-0.13

Q3'24

Missed

by $0.04

Q2'24

Beat

by $0.22

Q1'24

Est.

$-0.22

Q4'23

Beat

by $0.36

The last earnings report on November 14 showed earnings per share of -10 cents, missing the estimate of -7 cents. With 279.88K shares outstanding, the current market capitalization sits at 73.51M.

View a ticker or compare two or three

Compare

IMAB

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if bought

View Trends For IMAB
(Try 14 days for Free)

Ad is loading...

A.I.Advisor

published price charts

A.I. Advisor

published General Information

General Information

a clinical stage biopharmaceutical company, which engages in developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.

Industry Biotechnology

Profile

Fundamentals

Details

Industry

N/A

Address

555 West Haiyang Road

Phone

+86 2160578000

Employees

318

Web

https://www.i-mabbiopharma.com